TECFIDERA® (dimethyl fumarate) data reinforce strong, sustained efficacy for MS patients
Biogen announced new data that continue to support TECFIDERA® (dimethyl fumarate) as an effective, long-term treatment for people who are living with relapsing forms of multiple sclerosis. Data show TECFIDERA significantly reduced relapses and disability progression in newly-diagnosed RRMS patients. April 20, 2015